Hiroishi K, Kita H, Kojima M, Okamoto H, Moriyama T, Kaneko T, Ishikawa T, Ohnishi S, Aikawa T, Tanaka N, Yazaki Y, Mitamura K, Imawari M
Hepatology Division, Jichi Medical School, Tochigi, Japan.
Hepatology. 1997 Mar;25(3):705-12. doi: 10.1002/hep.510250336.
A cytotoxic T lymphocyte (CTL) response to the hepatitis C virus (HCV) nucleoprotein residues 88-96 that are the minimal and optimal epitope for human leukocyte antigen (HLA) B44-restricted CTLs was assessed in 27 HLA B44-positive patients with chronic HCV infection. Serum HCV RNA concentration and the amino acid sequence of the residues 81-100 were also determined. Three patients were infected with HCV with uncommon amino acid substitutions within the epitope. One was infected with HCV with an amino acid substitution in the flanking residues of the epitope. To stimulate CTLs in the peripheral blood, 9-mer peptides that corresponded to the residues 88-96 of the individual patients were synthesized and used. Seven of the 27 patients demonstrated a CTL response to the residues 88-96 with specific cytotoxic activities higher than 20%. The CTL activities were significantly higher in patients with a low titer of serum HCV RNA than in those with a high titer of serum HCV RNA (P = .0006). Some of the patients that demonstrated a CTL response to the residues 88-96 also demonstrated a CTL response to a newly identified HLA B44-restricted CTL epitope or a known HLA A11-restricted CTL epitope or both. No apparent association was observed between the CTL response and the stage of disease, or between the CTL response and the grade of necroinflammatory activity. The results suggest that the HLA B44-restricted CTLs together with other HCV-specific CTLs may inhibit the outgrowth of HCV and that high-titer infection with HCV may suppress the CTL responses.
在27例慢性丙型肝炎病毒(HCV)感染且人类白细胞抗原(HLA)B44阳性的患者中,评估了细胞毒性T淋巴细胞(CTL)对HCV核蛋白88 - 96位残基的反应,该残基是HLA B44限制性CTL的最小且最佳表位。同时还测定了血清HCV RNA浓度以及81 - 100位残基的氨基酸序列。3例患者感染的HCV在表位内有不常见的氨基酸替换。1例患者感染的HCV在表位侧翼残基有氨基酸替换。为刺激外周血中的CTL,合成并使用了与各患者88 - 96位残基对应的9聚体肽。27例患者中有7例对88 - 96位残基表现出CTL反应,其特异性细胞毒性活性高于20%。血清HCV RNA滴度低的患者的CTL活性显著高于血清HCV RNA滴度高的患者(P = .0006)。一些对88 - 96位残基表现出CTL反应的患者,也对新鉴定的HLA B44限制性CTL表位或已知的HLA A11限制性CTL表位或两者都表现出CTL反应。未观察到CTL反应与疾病阶段之间,或CTL反应与坏死性炎症活动程度之间有明显关联。结果表明,HLA B44限制性CTL与其他HCV特异性CTL一起可能抑制HCV的生长,并且HCV的高滴度感染可能抑制CTL反应。